US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

CJC-1295 + ipamorelin · tolerability · research use only

CJC-1295 and ipamorelin side effects, from the peptide research itself.

The honest starting point: there is no published human randomised trial of the specific CJC-1295 plus ipamorelin combination, so its adverse-event picture is assembled from the individual-component literature rather than a single combination table. What that literature does give is genuinely informative. CJC-1295 was studied in 65 healthy adults (Teichman et al., JCEM 2006) with no serious adverse events and injection-site reactions as the most common finding; ipamorelin (Raun et al., 1998) is defined by its selectivity — it triggers a growth-hormone pulse without the cortisol, prolactin or intense hunger that older secretagogues like GHRP-6 caused, even at doses far above the effective level. This page reproduces that component data as a research reference: the mild acute effects, the growth-hormone-class water retention, and why IGF-1 monitoring is the real safety variable. It is a summary of published research, not a human-use protocol or medical advice.

CJC-1295 + Ipamorelin blend — $119.99CJC-1295 / ipamorelin dosage

Injection-site reactions lead the profile

In the foundational CJC-1295 human study, injection-site reactions — mild redness, swelling or irritation at the subcutaneous site — were the most commonly reported adverse event, generally resolving with proper technique. This is the single most consistent finding across the component literature and, because both peptides are given subcutaneously, it applies to the blend as well. It is a local, technique-dependent effect rather than a systemic one.

Reconstitution & handling →

Water retention — the growth-hormone class effect

The most characteristic systemic effect is transient water retention or mild peripheral edema, driven by the sodium-retaining action of elevated GH and IGF-1. In the reported experience it is most pronounced in the first two to four weeks as GH output rises — described as feeling heavier with mild puffiness in the hands or face — and typically diminishes as the body adapts. It is a class effect of raising growth hormone, not specific to this pairing, and it is dose-related.

How the two clocks work →

Transient flushing, headache and fatigue

Acute post-injection effects reported in the literature include transient flushing, mild headache, lightheadedness and some fatigue shortly after dosing. Like the water retention, these are described as most noticeable in the first few injections and tapering thereafter. They reflect the acute hormonal surge rather than any cumulative toxicity, and the component trials classed the compounds as generally well tolerated.

Research dosing ranges →

Why ipamorelin is the 'clean' secretagogue

The defining safety feature of this pairing is what ipamorelin does not do. Published research (Raun 1998; and reviews of the GHRP class) showed ipamorelin stimulates GH release without raising ACTH, cortisol or prolactin — even at doses reported at up to ~200 times the effective GH-releasing amount — and without the strong hunger that GHRP-6 triggers through the ghrelin receptor. That selectivity is precisely why ipamorelin, not GHRP-2 or GHRP-6, is paired with CJC-1295: the GH signal stays clean of the stress-hormone and appetite noise.

Ipamorelin vs sermorelin →

IGF-1 elevation is the variable to watch

The literature's main long-term caution is not an acute symptom but a lab value: at higher doses or with the DAC-extended form, IGF-1 can be pushed above the age-adjusted reference range, and chronically supraphysiologic GH/IGF-1 is associated with joint discomfort and changes in insulin sensitivity. This is why researchers model periodic IGF-1 monitoring rather than open-ended escalation — the safety question is keeping IGF-1 in range, and the Titan blend is the no-DAC short-acting form specifically to avoid week-long over-elevation.

DAC vs no-DAC →

Research-use framing

Every effect described here comes from the individual-component peptide literature and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of any individual's experience and not as instructions for human use. No published human trial of the specific CJC-1295 + ipamorelin combination exists to date. Titan supplies the blend strictly as a research-use-only reagent, not for human or animal consumption. Nothing here is medical advice.

Lab testing & COA workflow →

The detail, in plain terms

The tolerability picture, at a glance.

Assembled from the individual-component research (CJC-1295: Teichman et al., JCEM 2006, n=65; ipamorelin: Raun et al., 1998 and GHRP-class reviews) and reproduced as a research reference. No combination-specific human trial exists; figures are qualitative because per-event incidence tables for these peptides were not published the way they are for approved drugs.

Injection-site reactions
Most commonly reported event (CJC-1295 human study); mild, local, technique-dependent.
Water retention / edema
GH-class effect from sodium retention; most pronounced weeks 1–4, usually transient.
Flushing / headache
Transient, acute post-injection; most noticeable in the first few doses.
Hunger
Minimal with ipamorelin — a deliberate advantage over GHRP-6, which strongly stimulates appetite.
Cortisol / prolactin
Not significantly raised by ipamorelin even at ~200× the effective dose (unlike GHRP-2/6).
Serious adverse events
None observed in the CJC-1295 healthy-adult study; GH pulse frequency preserved.
IGF-1 elevation
Can exceed the age-adjusted range at higher doses / DAC form — the main monitoring variable.
Onset & duration
Acute effects front-load in early weeks and taper; long-term caution is lab-based, not symptomatic.

Questions researchers ask

Before you order.

What are the most common CJC-1295 / ipamorelin side effects in the research?
The most consistently reported effects are injection-site reactions (mild local redness or swelling), transient water retention driven by elevated growth hormone, and short-lived flushing, headache or fatigue after dosing. These come from the individual-component peptide literature — CJC-1295's healthy-adult study and ipamorelin's characterisation research — and are reproduced as a research reference, not medical advice. There is no combination-specific human trial.
Does ipamorelin raise cortisol or cause hunger like other GH peptides?
No — that is its defining feature. Published research showed ipamorelin stimulates growth-hormone release without significantly raising ACTH, cortisol or prolactin, even at doses reported at up to roughly 200 times the effective GH-releasing amount, and without the strong appetite stimulation that GHRP-6 causes. That selectivity is exactly why ipamorelin is the secretagogue paired with CJC-1295 instead of the older GHRP-2 or GHRP-6.
Why does water retention happen and how long does it last?
Raising growth hormone and IGF-1 promotes sodium and water retention, which is a recognised class effect of any GH-axis compound. In the reported experience it is most noticeable in the first two to four weeks — mild puffiness or a heavier feeling in the hands and face — and typically diminishes as the body adapts. It is dose-related, so it tracks with how hard the GH axis is being pushed.
What is the main long-term safety concern?
Not an acute symptom but a laboratory value: IGF-1 rising above the age-adjusted reference range. Chronically supraphysiologic GH/IGF-1 is associated with joint discomfort and shifts in insulin sensitivity, so the research literature models periodic IGF-1 monitoring rather than continuous escalation. The Titan blend is the no-DAC, short-acting form specifically to produce physiologic pulses rather than week-long elevation.
Is CJC-1295 / ipamorelin approved for human use?
No. Neither peptide is an approved therapeutic in this combination, and there is no published human trial of the specific blend. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The tolerability information here summarises published component research and is not medical or dosing advice.

Related reading

Before you check out.